Positive opinion granted for KEYTRUDA plus chemotherapy for the first-line treatment of adult patients with primary advanced ...

Pembrolizumab (Keytruda, Merck) has picked up another indication — this time for the first-line treatment of unresectable ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced long-term overall survival (OS) data ...

For patients with early-stage triple-negative breast cancer, neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant ...

Notably, patients benefited from pembrolizumab regardless of whether they achieved a pathologic complete response (pCR), ...

Summit Therapeutics' ivonescimab poised for FDA approval, with the potential to disrupt the oncology market. Read more on ...

Summit Therapeutics stock rises 51% as ivonescimab shows promising results in lung cancer trial compared to Keytruda.

Merck (NYSE: MRK) stock has been a longtime winner for investors, returning 72% in the past five years. A major factor in ...

The event-free survival benefit with perioperative pembrolizumab in early NSCLC depends on the post-neoadjuvant residual ...

"Neoadjuvant pembrolizumab with chemotherapy followed ... KEYNOTE-522 was supported by Merck Sharp & Dohme. Schmid disclosed relationships with AstraZeneca, Daiichi Sankyo, Gilead, Merck, Novartis ...

At 10 years, more than one-third (34.0%) of patients with advanced melanoma were alive after treatment with KEYTRUDA, compared to 23.6% of patients treated with ipilimumab RAHWAY, N.J., September 15, ...

Merck & Co Inc.'s (MRK) anti-PD-1 therapy, KEYTRUDA (pembrolizumab), when combined with chemotherapy before surgery and continued as ...